Veradermics, Inc. (MANE)
122.28
+13.46
(+12.37%)
USD |
NYSE |
Oct 19, 16:00
128.00
+5.72
(+4.68%)
Pre-Market: 04:21
Veradermics Enterprise Value : 4.289B for Oct. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 19, 2026 | 4.289B |
| October 16, 2026 | 3.727B |
| October 15, 2026 | 3.988B |
| October 14, 2026 | 3.921B |
| October 13, 2026 | 4.038B |
| October 12, 2026 | 4.294B |
| October 09, 2026 | 4.650B |
| October 08, 2026 | 4.471B |
| October 07, 2026 | 3.816B |
| October 06, 2026 | 3.733B |
| October 05, 2026 | 4.147B |
| October 02, 2026 | 4.059B |
| October 01, 2026 | 4.078B |
| September 30, 2026 | 4.246B |
| September 29, 2026 | 4.103B |
| September 28, 2026 | 3.985B |
| September 25, 2026 | 4.051B |
| September 24, 2026 | 4.015B |
| September 23, 2026 | 4.018B |
| September 22, 2026 | 4.116B |
| September 21, 2026 | 3.893B |
| September 18, 2026 | 3.641B |
| September 17, 2026 | 3.721B |
| September 16, 2026 | 3.460B |
| September 15, 2026 | 3.521B |
| Date | Value |
|---|---|
| September 14, 2026 | 3.430B |
| September 11, 2026 | 3.316B |
| September 10, 2026 | 3.281B |
| September 09, 2026 | 3.345B |
| September 08, 2026 | 3.519B |
| September 04, 2026 | 3.296B |
| September 03, 2026 | 3.265B |
| September 02, 2026 | 3.294B |
| September 01, 2026 | 3.255B |
| August 31, 2026 | 3.292B |
| August 28, 2026 | 3.272B |
| August 27, 2026 | 3.434B |
| August 26, 2026 | 3.476B |
| August 25, 2026 | 3.457B |
| August 24, 2026 | 3.294B |
| August 21, 2026 | 3.476B |
| August 20, 2026 | 3.581B |
| August 19, 2026 | 3.828B |
| August 18, 2026 | 3.831B |
| August 17, 2026 | 3.702B |
| August 14, 2026 | 3.890B |
| August 13, 2026 | 3.818B |
| August 12, 2026 | 3.737B |
| August 11, 2026 | 3.732B |
| August 10, 2026 | 3.808B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.214T |
| ANI Pharmaceuticals, Inc. | 1.901B |
| Corcept Therapeutics, Inc. | 11.80B |
| Veru, Inc. | 16.28M |
| Johnson & Johnson | 639.46B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.50M |
| Total Expenses (Quarterly) | 23.50M |
| EPS Diluted (Quarterly) | -0.5625 |
| Earnings Yield | -2.13% |
| Normalized Earnings Yield | -2.130 |